RNVS Renovis (MM)

SOUTH SAN FRANCISCO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS) announced today Executive Chairman John Walker will present an overview of the company at the CIBC 18th Annual Healthcare Conference in New York, New York on Wednesday, November 7, 2007 at 11:30 a.m. Eastern Standard Time (8:30 a.m. PST). The presentation will be webcast. To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.renovis.com/ under the "Investors'" section. ABOUT RENOVIS Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has worldwide collaboration and license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists and an agreement with Genentech, Inc. in the areas of nerve growth and anti-angiogenesis. On September 19, 2007, Renovis announced the signing of a definitive merger agreement with Evotec AG (FSE: EVT) pursuant to which, subject to certain closing conditions set forth in the merger agreement, Renovis will be acquired by Evotec in a stock-for-stock transaction valued as of September 18, 2007, at approximately US$ 151.8 million. For more information, please visit http://www.renovis.com/. DATASOURCE: Renovis, Inc. CONTACT: Shari Annes, Investor Relations of Renovis, Inc., +1-650-888-0902, Web site: http://www.renovis.com/

Copyright